Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;57(4):1901192.
doi: 10.1183/13993003.01192-2019. Print 2021 Apr.

CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension

Affiliations
Free article

CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension

Stanislav Keranov et al. Eur Respir J. .
Free article

Abstract

The aim of our study was to analyse the protein expression of cartilage intermediate layer protein (CILP)1 in a mouse model of right ventricular (RV) pressure overload and to evaluate CILP1 as a biomarker of cardiac remodelling and maladaptive RV function in patients with pulmonary hypertension (PH).Pulmonary artery banding was performed in 14 mice; another nine mice underwent sham surgery. CILP1 protein expression was analysed in all hearts using Western blotting and immunostaining. CILP1 serum concentrations were measured in 161 patients (97 with adaptive and maladaptive RV pressure overload caused by PH; 25 with left ventricular (LV) hypertrophy; 20 with dilative cardiomyopathy (DCM); 19 controls without LV or RV abnormalities)In mice, the amount of RV CILP1 was markedly higher after banding than after sham. Control patients had lower CILP1 serum levels than all other groups (p<0.001). CILP1 concentrations were higher in PH patients with maladaptive RV function than those with adaptive RV function (p<0.001), LV pressure overload (p<0.001) and DCM (p=0.003). CILP1 showed good predictive power for maladaptive RV in receiver operating characteristic analysis (area under the curve (AUC) 0.79). There was no significant difference between the AUCs of CILP1 and N-terminal pro-brain natriuretic peptide (NT-proBNP) (AUC 0.82). High CILP1 (cut-off value for maladaptive RV of ≥4373 pg·mL-1) was associated with lower tricuspid annular plane excursion/pulmonary artery systolic pressure ratios (p<0.001) and higher NT-proBNP levels (p<0.001).CILP1 is a novel biomarker of RV and LV pathological remodelling that is associated with RV maladaptation and ventriculoarterial uncoupling in patients with PH.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Keranov reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study. Conflict of interest: O. Dörr reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study. Conflict of interest: L. Jafari has nothing to disclose. Conflict of interest: C. Troidl has nothing to disclose. Conflict of interest: C. Liebetrau reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study. Conflict of interest: S. Kriechbaum reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study. Conflict of interest: T. Keller has nothing to disclose. Conflict of interest: S. Voss has nothing to disclose. Conflict of interest: T. Bauer has nothing to disclose. Conflict of interest: J. Lorenz has nothing to disclose. Conflict of interest: M.J. Richter has nothing to disclose. Conflict of interest: K. Tello has nothing to disclose. Conflict of interest: H. Gall has nothing to disclose. Conflict of interest: H.A. Ghofrani has nothing to disclose. Conflict of interest: E. Mayer has nothing to disclose. Conflict of interest: C.B. Wiedenroth has nothing to disclose. Conflict of interest: S. Guth has nothing to disclose. Conflict of interest: H. Lörchner has nothing to disclose. Conflict of interest: J. Pöling has nothing to disclose. Conflict of interest: P. Chelladurai has nothing to disclose. Conflict of interest: S.S. Pullamsetti has nothing to disclose. Conflict of interest: T. Braun has nothing to disclose. Conflict of interest: W. Seeger has nothing to disclose. Conflict of interest: C.W. Hamm reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study. Conflict of interest: H. Nef reports grants from German Research Foundation (Project B07, Collaborative Research Center 1213-Pulmonary Hypertension and Cor Pulmonale), during the conduct of the study.

Comment in

Publication types

LinkOut - more resources